The growth hormone (GH) and insulin-like growth factor (IGF) system in girls and women with Turner syndrome

2006 ◽  
Vol 1298 ◽  
pp. 63-70 ◽  
Author(s):  
Wieland Kiess ◽  
Jurgen Kratzsch ◽  
Roland Pfaeffle
Keyword(s):  
Growth Hormone ◽  
Growth Factor ◽  
Turner Syndrome ◽  
Insulin Like Growth Factor ◽  
Igf System

scholarly journals The Role of the Growth Hormone/Insulin-Like Growth Factor System in Visceral Adiposity

2017 ◽  
Vol 10 ◽  
pp. 117862641770399 ◽  
Author(s):  
Moira S Lewitt
Keyword(s):  
Growth Hormone ◽  
Growth Factor ◽  
Visceral Obesity ◽  
Transgenic Animal ◽  
Visceral Adiposity ◽  
Future Research ◽  
Insulin Like Growth Factor ◽  
Igf System ◽  
Proliferation And Differentiation ◽  
Transgenic Animal Models

There is substantial evidence that the growth hormone (GH)/insulin-like growth factor (IGF) system is involved in the pathophysiology of obesity. Both GH and IGF-I have direct effects on adipocyte proliferation and differentiation, and this system is involved in the cross-talk between adipose tissue, liver, and pituitary. Transgenic animal models have been of importance in identifying mechanisms underlying these interactions. It emerges that this system has key roles in visceral adiposity, and there is a rationale for targeting this system in the treatment of visceral obesity associated with GH deficiency, metabolic syndrome, and lipodystrophies. This evidence is reviewed, gaps in knowledge are highlighted, and recommendations are made for future research.

Free dissociable insulin-like growth factor I (IGF-I), total IGF-I and their binding proteins in girls with Turner syndrome during long-term growth hormone treatment

2006 ◽  
Vol 65 (3) ◽  
pp. 310-319 ◽  
Author(s):  
Ellen M. N. Bannink ◽  
Jaap van Doorn ◽  
Theo Stijnen ◽  
Stenvert L. S. Drop ◽  
Sabine M. P. F. de Muinck Keizer-Schrama
Keyword(s):  
Growth Hormone ◽  
Growth Factor ◽  
Turner Syndrome ◽  
Binding Proteins ◽  
Growth Hormone Treatment ◽  
Hormone Treatment ◽  
Insulin Like Growth Factor ◽  
Factor I ◽  
Igf I

scholarly journals Effects of Recombinant Human Insulin-Like Growth Factor I (IGF-I) Therapy on the Growth Hormone-IGF System of a Patient with a Partial IGF-I Gene Deletion

1999 ◽  
Vol 84 (5) ◽  
pp. 1611-1616 ◽  
Author(s):  
Cecilia Camacho-Hübner ◽  
Katie A. Woods ◽  
Farideh Miraki-Moud ◽  
Peter C. Hindmarsh ◽  
Adrian J. Clark ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Growth Factor ◽  
Human Insulin ◽  
Gene Deletion ◽  
Insulin Like Growth Factor ◽  
Recombinant Human Insulin ◽  
Factor I ◽  
Igf System ◽  
Igf I ◽  
I Gene

Acute alterations in growth hormone-insulin-like growth factor axis in humans injected with endotoxin

1997 ◽  
Vol 273 (1) ◽  
pp. R371-R378 ◽  
Author(s):  
C. H. Lang ◽  
V. Pollard ◽  
J. Fan ◽  
L. D. Traber ◽  
D. L. Traber ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Growth Factor ◽  
Insulin Like Growth Factor ◽  
Maximal Increase ◽  
Igf System ◽  
Igf I ◽  
Igf Binding ◽  
Acute Changes ◽  
Transient Elevation ◽  
Igf Binding Protein

The purpose of the present study was to characterize the acute changes in the insulin-like growth factor (IGF) system in humans after administration of endotoxin (lipopolysaccharide; LPS). Escherichia coli LPS (4 ng/kg) was injected intravenously into healthy adults, and serial blood samples were collected for the next 5 h; subjects injected with saline served as time-matched controls. LPS administration resulted in a gradual decrease in the total extractable IGF-I concentration, which was reduced by approximately 20% over the final 2 h of the experiment; levels of free IGF-I were not significantly altered. LPS also produced a marked but transient elevation in growth hormone (GH) concentration. IGF-binding protein (BP)-1 levels were elevated more than fivefold 2 h after LPS injection, and thereafter levels gradually returned toward baseline. IGFBP-2 concentration also increased after LPS injection, but the maximal increase (approximately 50% above basal) was observed during the final 2 h of the protocol. In contrast, IGFBP-3 levels did not vary over the period examined in response to LPS, and there was no apparent increase in number of BP-3 proteolytic fragments. Cortisol levels were increased early and remained two- to threefold above baseline throughout the protocol. No significant alterations in serum concentration of glucose or insulin were noted. LPS also produced an early elevation in tumor necrosis factor and a later increase in interleukin-6. These data indicate that the acute changes in the GH-IGF axis in humans in response to LPS are comparable with those observed in humans in other traumatic conditions and in animal models of endotoxemia and infection.

scholarly journals Recombinant growth hormone therapy in children with Turner Syndrome in Korea: a phase III Randomized Trial

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Jinsup Kim ◽  
Min-Sun Kim ◽  
Byung-Kyu Suh ◽  
Cheol Woo Ko ◽  
Kee-Hyoung Lee ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Growth Factor ◽  
Turner Syndrome ◽  
Standard Deviation Score ◽  
Phase Iii ◽  
Height Velocity ◽  
Insulin Like Growth Factor ◽  
Efficacy And Safety ◽  
Korean Children ◽  
Comparator Group

Abstract Background Short stature is the most consistent characteristic feature of Turner syndrome (TS). To improve final heights of children with TS effectively, it is important to provide them with early and appropriate treatment using growth hormone (GH). The objective of this study was to assess the efficacy and safety of a new recombinant human GH, Growtropin®-II (DA-3002, Dong-A ST Co., Ltd) versus a comparator (Genotropin®, Pfizer Inc.) for Korean children with TS. Methods This open-label, active-controlled, parallel-group, randomized controlled phase III trial was conducted at 11 hospitals in Korea. Eligible patients (n = 58) were randomized to two groups: 1) DA-3002 group (administrated with DA-3002 at 0.14 IU [0.0450–0.050 mg] /kg/day); and 2) comparator group (administrated with the comparator at 0.14 IU [0.0450–0.050 mg] /kg/day). Results The change from baseline in annualized height velocity (HV) after a 52-week treatment period was 4.15 ± 0.30 cm/year in the DA-3002 group and 4.34 ± 0.29 cm/year in the comparator group. The lower bound of 95% two-sided confidence interval for group difference in the change of annualized HV (− 1.02) satisfied the non-inferiority margin (− 1.5). The change in height standard deviation score (HtSDS) at 52-week was 0.70 ± 0.23 for the DA-3002 group and 0.66 ± 0.39 for the comparator group, showing no significant (p = 0.685) difference between the two groups. The change of skeletal maturity defined as change in bone age/change in chronological age between the two groups was not significantly different (1.25 ± 0.58 for the DA-3002 group and 1.47 ± 0.45 for the comparator group, p = 0.134). Changes from baseline in serum insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) after 52 weeks of treatment did not differ significantly between the two groups (p = 0.565 and p = 0.388, respectively) either. The occurrence of adverse events was not statistically different between groups. Conclusions This study demonstrates that the efficacy and safety of GH treatment with DA-3002 in children with TS are comparable with those of the comparator. It is expected to analysis the long-term effect of DA-3002 on the increase of final adult height in children with TS and possible late-onset complications in the future. Trial registration The study was registered at ClinicalTrials.gov. ClinicalTrials.gov identifier: NCT01813630 (19/03/2013).

Sign in / Sign up

Export Citation Format

Share Document